Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 7/20 | 0.33 |
| ▸ | JAK3 | P52333 | 7/20 | 0.33 |
| ▸ | JAK1 | P23458 | 6/20 | 0.33 |
| ▸ | TYK2 | P29597 | 2/20 | 0.33 |
| ▸ | EEF2K | O00418 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | DRD1 | P21728 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6648240 | 0.86 | EEF2K (0.36) | JAK2JAK3JAK1TYK2EEF2K | |
| SCHEMBL6671328 | 0.78 | EEF2K (0.35) | JAK2JAK3JAK1TYK2EEF2K | |
| SCHEMBL7099119 | 0.75 | KCNH2 (0.34) | OPRM1 | |
| Hydrochloric Acid SCHEMBL7097458 | 0.74 | KCNH2 (0.46) | EEF2KOPRM1 | |
| SCHEMBL6378161 | 0.74 | OPRL1 (0.34) | JAK2JAK3JAK1TYK2EEF2K | |
| Hydrochloric Acid SCHEMBL6669411 | 0.74 | KCNH2 (0.46) | EEF2KOPRM1 | |
| Hydrochloric Acid SCHEMBL6673499 | 0.72 | JAK2 (0.31) | JAK2JAK3JAK1TYK2DRD1 | |
| SCHEMBL2903740 | 0.68 | KCNH2 (0.50) | OPRM1 | |
| SCHEMBL6377126 | 0.67 | KCNH2 (0.34) | EEF2K | |
| Hydrochloric Acid SCHEMBL6669502 | 0.66 | KCNH2 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1401830-A2 | QUINAZOLINEDIONES AS ANTIBACTERIAL AGENTS | Warner-Lambert Company LLC (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030114666-A1 | Having quinazolindione core structure; non-antibiotic resistance | WARNER-LAMBERT COMPANY | 2003-06-19 | — | — | US | disclosed |
| WO-2002102793-A2 | QUINAZOLINEDIONES AS ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114666-A1 | Having quinazolindione core structure; non-antibiotic resistance | ABCC1, RPS6KA1, SIGMAR1 | JAK2 1738/4885JAK3 1181/4885JAK1 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.